|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Operating lease and right of use asset | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Due from LeSalon | ||||||||||||||||||||
| Deposit on asset purchase | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Furniture and equipment | ||||||||||||||||||||
| Domain list | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Unearned income | ||||||||||||||||||||
| Common stock payable | ||||||||||||||||||||
| Notes payable to shareholders, net | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Accounts payable and accrued expenses - related parties | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Due to Applife Holdings | ||||||||||||||||||||
| Derivative liability - common stock warrants | ||||||||||||||||||||
| Due to officer | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Related party advances | ||||||||||||||||||||
| Promissory notes - non-related parties | ||||||||||||||||||||
| Promissory notes - related parties | ||||||||||||||||||||
| Convertible promissory notes, net of discounts | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible notes payable to stockholder - noncurrent, net | ||||||||||||||||||||
| Convertible preferred stock liability - Series B preferred stock, $0.001 par value per share, 20,000 shares authorized and 14,515 and 12,855 shares issued and outstanding as of June 30, 2026 and 2025, respectively; stated value of $1,451,500 and $1,285,500 as of June 30, 2026 and 2025 | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' deficit | ||||||||||||||||||||
| Preferred shares | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Common Stock of $0.001 par value - Authorized: 20,000,000 and 5,000,000,000 shares as of June 30, 2026 and 2025, Issued and outstanding: 8,202,083 and 8,000,000 shares as of June 30, 2026 and 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated (deficit) | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||||
Loading...
